Compare D R Horton Inc (DHI) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? D R Horton Inc trades at $134.2 (market cap $37.99B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.39 (market cap $2.27B). The key difference: D R Horton Inc is far larger — about 16.7× SELLAS Life Sciences Group Inc. Common Stock's market cap, and D R Horton Inc pays a 1.33% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| DHI | SLS | |
|---|---|---|
Market Cap | $37.99B | $2.27B |
Volume | 2,974,460 | 4,179,659 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $15.46 |
52-Week Low | $132.53 | $1.39 |
Typical Hold Time | 46 Days | — |
Enterprise Value | $43.09B | $2.14B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $133.28, down 2.54% on the day amid broader housing sector weakness. The stock shows bearish technical signals with oversold RSI conditions, while fundamentals remain solid with consistent earnings beats and attractive valuation multiples. Recent news highlights pressure from rising mortgage rates and housing market concerns, though the company maintains strong operational cash flow and analyst support.
DHI presents a value opportunity with below-market P/E of 12.95 and 47% analyst buy ratings, but faces headwinds from potential 9% mortgage rates and declining home sales. The consensus price target of $156.57 offers 17% upside, though investors should monitor Q3 2026 earnings on October 29 for margin sustainability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
